Modis Therapeutics Announces that MT1621 Receives Breakthrough Therapy Designation from FDA for the Treatment of TK2 Deficiency
Threat Stack Announces the Completion of its Annual Type 2 SOC 2 Examination
Innovent Announces a Collaboration with Chipscreen Biosciences to Evaluate the Combination Therapy in Colorectal Cancer Patients
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for Alzheimer’s Disease
